학술논문

Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States: a real-world analysis
Document Type
Short Communication
Source
In Blood Advances 13 February 2024 8(3):549-552
Subject
Clinical Trials and Observations
Health Services and Outcomes
Lymphoid Neoplasia
Language
ISSN
2473-9529